Turner Syndrome Market Forecasts to 2030 – Global Analysis By Type (Mosaic Turner Syndrome and Classical Turner Syndrome), Drug Type (Oxandrolone, Oxandrin, Norditropin, Somatropin, Genotropin, Humatrope, Zomacton and Nutropin), Therapy Type, Diagnosis, R

Turner Syndrome Market Forecasts to 2030 – Global Analysis By Type (Mosaic Turner Syndrome and Classical Turner Syndrome), Drug Type (Oxandrolone, Oxandrin, Norditropin, Somatropin, Genotropin, Humatrope, Zomacton and Nutropin), Therapy Type, Diagnosis, Route Of Administration, End User and By Geography

According to Stratistics MRC, the Global Turner Syndrome Market is accounted for $4.23 billion in 2023 and is expected to reach $7.29 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Turner syndrome is a chromosomal condition that affects females and results from a missing or incomplete X chromosome. Typically, females have two X chromosomes (XX), but individuals with Turner syndrome have either a missing X chromosome (X0) or abnormalities in one of the X chromosomes. Girls with turner syndrome often have specific physical characteristics including short stature, a webbed neck (extra folds of skin), a broad chest, low-set ears, and a high-arched palate.

According to the National Library of Medicine in 2017, about 1 in 2,500 new-born girls, worldwide, were affected with the Turner Syndrome.

Market Dynamics:

Driver:

Rising patient advocacy and awareness

Patient advocacy plays a crucial role in advocating for improved access to healthcare services and treatments. It often extends to policy initiatives aimed at improving the overall landscape for individuals with rare diseases like turner syndrome. Increased awareness often leads to early detection of Turner syndrome. It plays a crucial role in raising awareness, supporting research, and advocating for better treatment options. These groups facilitates collaboration between researchers, clinicians, and pharmaceutical companies.

Restraint:

Limited patient population

Turner Syndrome is a rare disorder which occurs in mostly one out of 2000 girls. So, there is less availability of natural history data, which is crucial for understanding the progression of the disease. Limited patient numbers makes it challenging to gather sufficient real-world evidence, potentially hindering the understanding of the long-term impact of therapies. Also, establishing the value of a therapy and securing reimbursement can be more complex. This aspect raises the complexities and hampers the market growth.

Opportunity:

Unmet medical needs

Turner Syndrome is a rare disorder and it presents several unmet medical needs that need effective and targeted therapies. Addressing these unmet medical needs requires collaboration between healthcare professionals, researchers, and pharmaceutical companies. The development of targeted therapies could significantly improve the management of Turner Syndrome, potentially leading to more effective and personalized treatment options. Pharmaceutical companies may see this as an opportunity to develop innovative treatments which in turn accelerates the market expansion.

Threat:

High development costs

The development of therapies for rare conditions such as turner syndrome often faces unique challenges, leading to high development costs. The limited number of potential patients makes it economically challenging for pharmaceutical companies to invest in the development of drugs or therapies for turner syndrome. Also, understanding the underlying genetic mechanisms, conducting preclinical studies, and navigating the regulatory processes for rare diseases require specialized expertise and resources. The combination of these factors can hamper the growth of the market.

Covid-19 Impact

Global healthcare services have been severely impacted by the COVID-19 epidemic. Due to the pandemic, resources were redirected, which caused delays in the treatment of non-urgent medical disorders, such as Turner syndrome. Patients have faced challenges in accessing regular check-ups, treatments, and support services. Additionally, the supply chain for the pharmaceutical sector experienced interruptions that impacted the availability of drugs and other healthcare supplies related to Turner syndrome. The market has further recovered to its pre-pandemic level.

The genotropin segment is expected to be the largest during the forecast period

The genotropin segment is estimated to have a lucrative growth. Genotropin is often used as part of a comprehensive treatment approach that includes hormone replacement therapy and other interventions to address various aspects of turner syndrome. It contributes to an improved quality of life for individuals with turner syndrome. It exhibits numerous benefits such as improved body composition, bone health, cardiovascular health, improvement of short stature and overall body growth.

The prenatal testing segment is expected to have the highest CAGR during the forecast period

The prenatal testing segment is anticipated to witness the highest CAGR growth during the forecast period. Prenatal testing plays a crucial role in the early diagnosis of turner syndrome. This early diagnosis can lead to timely interventions and appropriate management strategies, potentially improving outcomes for the affected individual. Knowing about the disorder during pregnancy allows parents to emotionally prepare for the challenges associated with the condition. As technology and genetic testing methods continue to advance, the accuracy and accessibility of prenatal testing for turner syndrome are likely to improve, further enhancing its role in patient care and family planning.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing awareness for women health, rising healthcare expenditures and growing healthcare sector. The Indian healthcare sector was one of the fastest growing industries. The developing countries like the India and China are investing heavily on healthcare infrastructure, professional doctors and R&D activities. Therefore, the increasing expenditure coupled with rising regularity of genetic disorders in females leads to the growth of the turner syndrome market in this region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is home to several key players such as Novartis, Ipsen and Sanofi Genzym. These companies invest hugely on research activities related to rare genetic diseases. They often bring out latest innovations and solutions. Further, rise in technological innovations for rare disorders, huge patient population, increasing awareness regarding down syndromes and growing biotechnology sector are boosting the region’s market growth.

Key players in the market

Some of the key players profiled in the Turner Syndrome Market include Smiths Group, Pfizer Inc., Rocket Medical PLC, Medtronic, Novo Nordisk, Sanofi, Cooper Pharma, Eli Lilly and Company, Genentech, Lupin Pharmaceuticals Inc, Sandoz International GmbH, AbbVie Inc., Codexis, Merck & Co., American Gene Technologies, Johnson & Johnson Services Inc, F. Hoffmann-La Roche Limited, Ultragenyx Pharmaceutical, Abbott Laboratories and BioMarin.

Key Developments:

In October 2023, Novo Nordisk, a subsidiary of Novo Holdings AS, unveils Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

In March 2023, Sanofi and Provention Bio Inc, have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc. The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes.

Types Covered:
• Mosaic Turner Syndrome
• Classical Turner Syndrome

Drug Types Covered:
• Oxandrolone
• Oxandrin
• Norditropin
• Somatropin
• Genotropin
• Humatrope
• Zomacton
• Nutropin

Therapy Types Covered:
• Progesterone Replacement Therapy
• Oestrogen Replacement Therapy
• Growth Hormone Therapy
• Psychological Therapy
• Other Therapy Types

Diagnosis Covered:
• Physical Examination
• Karyotyping
• Prenatal Testing
• Other Diagnosis

Route Of Administrations Covered:
• Oral
• Sub-cutaneous
• Intravenous
• Intramuscular
• Other Route Of Administrations

End Users Covered:
• Research Organizations
• Hospitals & Clinics
• Academic Institutes
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments

- Strategic recommendations for the new entrants

- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030

- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends

- Company profiling with detailed strategies, financials, and recent developments

- Supply chain trends mapping the latest technological advancements